García-Pérez LE - Search Results

1

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.

Cukierman-Yaffe T, Gerstein HC, Colhoun HM, Diaz R, García-Pérez LE, Lakshmanan M, Bethel A, Xavier D, Probstfield J, Riddle MC, Rydén L, Atisso CM, Hall S, Rao-Melacini P, Basile J, Cushman WC, Franek E, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T. Cukierman-Yaffe T, et al. Among authors: garcia perez le. Lancet Neurol. 2020 Jul;19(7):582-590. doi: 10.1016/S1474-4422(20)30173-3. Lancet Neurol. 2020. PMID: 32562683 Clinical Trial.

2

Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers.

Anderson JE, Thieu VT, Boye KS, Hietpas RT, Garcia-Perez LE. Anderson JE, et al. Postgrad Med. 2016 Nov;128(8):810-821. doi: 10.1080/00325481.2016.1218260. Epub 2016 Aug 12. Postgrad Med. 2016. PMID: 27488824 Review.

3

Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.

Gallwitz B, Dagogo-Jack S, Thieu V, Garcia-Perez LE, Pavo I, Yu M, Robertson KE, Zhang N, Giorgino F. Gallwitz B, et al. Diabetes Obes Metab. 2018 Feb;20(2):409-418. doi: 10.1111/dom.13086. Epub 2017 Oct 5. Diabetes Obes Metab. 2018. PMID: 28817231 Free PMC article. Clinical Trial.

4

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.

Ludvik B, Frías JP, Tinahones FJ, Wainstein J, Jiang H, Robertson KE, García-Pérez LE, Woodward DB, Milicevic Z. Ludvik B, et al. Lancet Diabetes Endocrinol. 2018 May;6(5):370-381. doi: 10.1016/S2213-8587(18)30023-8. Epub 2018 Feb 23. Lancet Diabetes Endocrinol. 2018. PMID: 29483060 Free article. Clinical Trial.

5

Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.

Mathieu C, Del Prato S, Botros FT, Thieu VT, Pavo I, Jia N, Haupt A, Karanikas CA, García-Pérez LE. Mathieu C, et al. Diabetes Obes Metab. 2018 Aug;20(8):2023-2028. doi: 10.1111/dom.13313. Epub 2018 May 2. Diabetes Obes Metab. 2018. PMID: 29603872 Free PMC article. Clinical Trial.

6

Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.

Boye KS, Riddle MC, Gerstein HC, Mody R, Garcia-Perez LE, Karanikas CA, Lage MJ, Riesmeyer JS, Lakshmanan MC. Boye KS, et al. Diabetes Obes Metab. 2019 Jun;21(6):1299-1304. doi: 10.1111/dom.13649. Epub 2019 Mar 12. Diabetes Obes Metab. 2019. PMID: 30714309 Free PMC article.

7

Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.

Giorgino F, Yu M, Haupt A, Milicevic Z, García-Pérez LE. Giorgino F, et al. Diabetes Obes Metab. 2019 Nov;21(11):2570-2575. doi: 10.1111/dom.13844. Epub 2019 Aug 16. Diabetes Obes Metab. 2019. PMID: 31364266 Free PMC article.

8

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).

Matza LS, Boye KS, Stewart KD, Coyne KS, Wullenweber PK, Cutts KN, Jordan JB, Wang Q, Yu M, Currie BM, Malley KG, Ishak KJ, Hietpas RT, García-Pérez LE. Matza LS, et al. Among authors: garcia perez le. Diabetes Obes Metab. 2020 Mar;22(3):355-364. doi: 10.1111/dom.13902. Epub 2019 Dec 19. Diabetes Obes Metab. 2020. PMID: 31646727 Free PMC article. Clinical Trial.

9

Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials.

Jódar E, Romera I, Wang Q, Roche SL, García-Pérez LE. Jódar E, et al. Among authors: garcia perez le. Diabetes Obes Metab. 2022 Apr;24(4):631-640. doi: 10.1111/dom.14615. Epub 2021 Dec 19. Diabetes Obes Metab. 2022. PMID: 34866291 Free PMC article.

10

Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK.

Boye KS, Stein D, Matza LS, Jordan J, Yu R, Norrbacka K, Hassan SW, García-Pérez LE. Boye KS, et al. Drugs R D. 2019 Jun;19(2):213-225. doi: 10.1007/s40268-019-0273-0. Drugs R D. 2019. PMID: 31115873 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page